Canevelli Marco, Cesari Matteo, Lucchini Flaminia, Valletta Martina, Sabino Michele, Lacorte Eleonora, Vanacore Nicola, Bruno Giuseppe
Department of Neurology and Psychiatry, "Sapienza" University of Rome, Rome, Italy.
Gérontopôle, Centre Hospitalier Universitaire de Toulouse, Toulouse, France.
J Am Geriatr Soc. 2017 Sep;65(9):2071-2073. doi: 10.1111/jgs.14989. Epub 2017 Jul 6.
To determine whether neuropsychiatric symptoms (NPSs) are adequately considered in clinical research on Alzheimer's disease (AD).
Systematic review.
Randomized controlled trials (RCTs) recruiting individuals with AD and published during the last 10 years in 16 major general medicine, neurology, psychiatry, and geriatric psychiatry journals and RCTs registered on clinicaltrials.gov and currently enrolling individuals with AD.
Individuals with AD.
Outcome measures adopted by the included studies.
Only 21.4% of the included studies identified through the bibliographic searches had measures of NPSs as a primary outcome. Only 17.7% of the studies retrieved on clinicaltrials.gov made a specific effort to test the effect of pharmacological or nonpharmacological interventions on NPSs.
These findings show how rarely previous and current research on AD has considered NPSs as primary research targets. Although these symptoms are widely recognized as the most-stressful and -challenging manifestations of dementia, they are addressed much less often than other research targets.
确定在阿尔茨海默病(AD)的临床研究中是否充分考虑了神经精神症状(NPSs)。
系统评价。
在过去10年中于16种主要的普通医学、神经学、精神病学和老年精神病学杂志上发表的招募AD患者的随机对照试验(RCTs),以及在clinicaltrials.gov上注册且目前正在招募AD患者的RCTs。
AD患者。
纳入研究采用的结局指标。
通过文献检索确定的纳入研究中,仅有21.4%将NPSs测量指标作为主要结局。在clinicaltrials.gov上检索到的研究中,仅有17.7%专门致力于测试药物或非药物干预对NPSs的影响。
这些发现表明,以往和当前关于AD的研究极少将NPSs视为主要研究目标。尽管这些症状被广泛认为是痴呆最具压力和挑战性的表现,但与其他研究目标相比,对它们的研究却少得多。